Literature DB >> 19614671

Haemorrhoids - a collagen disease?

S Willis1, K Junge, R Ebrahimi, A Prescher, V Schumpelick.   

Abstract

OBJECTIVE: The cause of haemorrhoidal disease is unknown, epidemiological data and histopathological findings support the hypothesis that reduced connective tissue stability is associated with the incidence of haemorrhoids. Therefore the aim of this study was to analyse the quantity and quality of collagen formation in the corpus cavernosum recti in patients with III°/IV° haemorrhoids in comparison with persons without haemorrhoids.
METHOD: Haemorrhoidectomy specimens of 31 patients with III°/IV° haemorrhoids were examined. The specimens of 20 persons who died a natural death and who had no haemorrhoidal disease served as the controls. The amount of collagen was estimated photometrically by calculating the collagen/protein ratio. The collagen I/III ratio served as parameter for the quality of collagen formation and was calculated using cross polarization spectroscopy.
RESULTS: Patients with haemorrhoids had a significantly reduced collagen/protein ratio (42.2 ± 16.2μg/mg vs 72.5±31.0μg/mg; P= 0.02) and a significantly reduced collagen I/III ratio (2.0±0.1 vs 4.6±0.3; P<0.001) compared with persons without haemorrhoidal disease. There was no correlation with patients' age or gender.
CONCLUSIONS: There is a fundamental disorder of collagen metabolism in patients with haemorrhoidal disease. It remains unclear whether this is due to exogenous or endogenous influences.
© 2010 The Authors. Colorectal Disease © 2010 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19614671     DOI: 10.1111/j.1463-1318.2009.02010.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  8 in total

1.  Efficacy and tolerability of hyaluronic acid, tea tree oil and methyl-sulfonyl-methane in a new gel medical device for treatment of haemorrhoids in a double-blind, placebo-controlled clinical trial.

Authors:  N Joksimovic; G Spasovski; V Joksimovic; V Andreevski; C Zuccari; C F Omini
Journal:  Updates Surg       Date:  2012-04-11

Review 2.  Conservative and surgical treatment of haemorrhoids.

Authors:  Donato F Altomare; Simona Giuratrabocchetta
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-06-11       Impact factor: 46.802

Review 3.  Rethinking What We Know About Hemorrhoids.

Authors:  Robert S Sandler; Anne F Peery
Journal:  Clin Gastroenterol Hepatol       Date:  2018-03-27       Impact factor: 11.382

4.  Direct and recurrent inguinal hernias are associated with ventral hernia repair: a database study.

Authors:  Nadia A Henriksen; Lars T Sorensen; Morten Bay-Nielsen; Lars N Jorgensen
Journal:  World J Surg       Date:  2013-02       Impact factor: 3.352

5.  Abnormalities in collagen composition may contribute to the pathogenesis of hemorrhoids: morphometric analysis.

Authors:  Y Y Nasseri; E Krott; K M Van Groningen; M Berho; M C Osborne; S Wollman; E G Weiss; S D Wexner
Journal:  Tech Coloproctol       Date:  2014-11-09       Impact factor: 3.781

6.  Risk factors for hemorrhoidal disease among healthy young and middle-aged Korean adults.

Authors:  Yun Soo Hong; Kyung Uk Jung; Sanjay Rampal; Di Zhao; Eliseo Guallar; Seungho Ryu; Yoosoo Chang; Hyung Ook Kim; Hungdai Kim; Ho-Kyung Chun; Chong Il Sohn; Hocheol Shin; Juhee Cho
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

7.  Ehlers-danlos syndrome-hypermobility type and hemorrhoids.

Authors:  Timothy P Plackett; Edward Kwon; Ronald A Gagliano; Robert C Oh
Journal:  Case Rep Surg       Date:  2014-04-15

8.  A Randomized Controlled Trial Comparing Suture-Fixation Mucopexy and Doppler-Guided Hemorrhoidal Artery Ligation in Patients with Grade III Hemorrhoids.

Authors:  Min Zhai; Yong-An Zhang; Zhen-Yi Wang; Jian-Hua Sun; Jie Wen; Qi Zhang; Jin-De Li; Yi-Zheng Wu; Feng Zhou; Hui-Lei Xu
Journal:  Gastroenterol Res Pract       Date:  2016-03-15       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.